1598201
USP
Raloxifene hydrochloride
United States Pharmacopeia (USP) Reference Standard
别名:
Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C28H27NO4S · HCl
CAS号:
分子量:
510.04
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
raloxifene
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
Cl[H].Oc1ccc(cc1)-c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4
InChI
1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H
InChI 密鑰
BKXVVCILCIUCLG-UHFFFAOYSA-N
基因資訊
human ... ESR2(2100)
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Raloxifene hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
生化／生理作用
Raloxifene is a selective estrogen receptor modulator (SERM); acts as an anti-estrogen in both breast and uterine tissue while being estrogenic in bone. May have efficacy against estrogen-sensitive cancers.
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Carc. 2 - Repr. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
W Khovidhunkit et al.
Annals of internal medicine, 130(5), 431-439 (1999-03-06)
To review clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was recently approved for the prevention of osteoporosis in postmenopausal women. English-language articles published from 1980 to May 1998 were identified through MEDLINE searches. Bibliographies, book chapters
[Raloxifene hydrochloride].
Akira Itabashi
Nihon rinsho. Japanese journal of clinical medicine, 62 Suppl 2, 528-535 (2004-03-24)
A Saitta et al.
Cardiovascular drug reviews, 19(1), 57-74 (2001-04-21)
Raloxifene hydrochloride binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators (SERMs). Tissue selectivity of raloxifene may be achieved through several mechanisms: the ligand structure
Roberta Fontana et al.
Endocrinology, 155(6), 2213-2221 (2014-03-19)
Estrogens play an important role in the regulation of energy homeostasis in female mammals and a reduced ovarian function, due to natural aging or surgery, is associated with body weight increase and fat redistribution. This disruption of energy homeostasis may
Ibrahim A Abdelazim et al.
Archives of osteoporosis, 9, 189-189 (2014-07-20)
Osteoporosis is a major cause of mortality and morbidity worldwide. Decreased bone turnover markers and increased lumbar spine and total hip bone mineral density (BMD) in raloxifene-treated women add further support to the idea that raloxifene is an effective well-tolerated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门